Accelerate Diagnostics

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Company Growth (employees)
Type
Public
HQ
Tucson, US
Founded
2004
Size (employees)
193 (est)
Accelerate Diagnostics was founded in 2004 and is headquartered in Tucson, US

Accelerate Diagnostics Office Locations

Accelerate Diagnostics has offices in Tucson and Castelldefels
Tucson, US (HQ)
3950 S Country Club Rd
Castelldefels, ES
1 Carrer Esteve Terradas

Accelerate Diagnostics Data and Metrics

Accelerate Diagnostics Financial Metrics

Accelerate Diagnostics's revenue was reported to be $246 k in FY, 2016 which is a 67% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

246 k

Revenue growth (FY, 2015 - FY, 2016), %

67%

Net income (FY, 2016)

(66.4 m)

EBIT (FY, 2016)

(66.5 m)

Market capitalization (26-May-2017)

1.5 b

Closing share price (26-May-2017)

28.7

Cash (31-Dec-2016)

19.2 m
Accelerate Diagnostics's current market capitalization is $1.5 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

48.3 k122 k147 k246 k

Revenue growth, %

153%20%67%

Operating expense total

3.4 m45.7 m66.7 m

EBIT

(15.3 m)(31.5 m)(45.5 m)(66.5 m)

EBIT margin, %

(31709%)(25834%)(30986%)(27033%)

Pre tax profit

(3.4 m)(45.5 m)(66.1 m)

Net Income

(15.3 m)(30.9 m)(45.5 m)(66.4 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

30 m53.6 m120.6 m19.2 m

Accounts Receivable

24.4 k78 k77 k34 k

Inventories

Current Assets

42.1 m67.1 m134.2 m78.4 m

PP&E

1 m2.5 m5 m4.3 m

Total Assets

43.4 m69.8 m139.3 m82.9 m

Accounts Payable

540.4 k2.1 m2.6 m992 k

Current Liabilities

1.1 m2.8 m5.3 m4 m

Retained Earnings

(34.5 m)(65.4 m)(110.9 m)(177.3 m)

Total Equity

41.5 m66 m133 m77.8 m

Financial Leverage

1 x1.1 x1 x1.1 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.4 m)(3.4 m)(45.5 m)(66.4 m)

Depreciation and Amortization

42.7 k43 k1.8 m2.4 m

Accounts Receivable

(13 k)(13 k)1 k43 k

Inventories

10.3 k10 k

Accounts Payable

236.6 k236 k329 k(1.2 m)

Cash From Operating Activities

18 m(2.1 m)(35.1 m)(53.4 m)

Cash From Investing Activities

(158.3 k)(158 k)(2.7 m)(49.6 m)

Cash From Financing Activities

100 k100 k104.8 m1.8 m
Y, 2016

Financial Leverage

1.1 x

Accelerate Diagnostics Market Value History

Accelerate Diagnostics Online and Social Media Presence

Accelerate Diagnostics News and Updates

Accelerate Diagnostics Company Life and Culture

You may also be interested in